Jump to content
Acne.org
Search In
Find results that contain...
Find results in...

Recommended Posts

Dapsone 5% topical gel

Aczoneâ„¢

http://www.multum.com/dapsone.htm

Dapsone in a gel formulation, at concentrations of 3 and 5% has been experimentally used for the last 3 years. It appears to be a new and promising therapeutic modality for moderate to moderately severe acne. It has not been available in the past as it is highly insoluble in the aqueous solvents traditionally used in dermatological preparations. New technologies provide a formulation based on the solvent ethoxydiglycol, which will eventually solve the problem. The delivery is through the skin in two stages; with preferential uptake of the drug immediately in the skin oil in and near the pilosebaceous follicle, followed by slower release from a suspension of microparticles in the surrounding region (Dr. D. Osborne, 2001, 59th Annual Meeting of the American Academy of Dermatology, Washington, D.C.). Clinical studies conducted have demonstrated that numbers of both inflammatory and non-inflammatory lesions were reduced by 50% at the end of a 28-day treatment period.

Don't know if it is prescription or not.

Link to comment
Share on other sites

Here are more links.

http://www.docguide.com/news/content.nsf/n...5256FAF005250A7

http://www.pslgroup.com/dg/24a6de.htm

http://www.dermatologytimes.com/dermatolog...ail.jsp?id=3864

http://my.webmd.com/content/Article/109/109115.htm

ACZONEâ„¢ GEL IS APPROVED FOR THE TREATMENT OF ACNE BY THE FDA

CONFERENCE CALL TO DISCUSS ACZONEâ„¢ STRATEGY

FOR IMMEDIATE RELEASE JULY 7, 2005

VANCOUVER, BCâ€â€QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) to market ACZONEâ„¢ (dapsone) Gel, 5% for the topical treatment of acne vulgaris.

Patients will need to be screened to detect if they are predisposed to one type of anemia (hemolytic anemia) because of a specific enzyme deficiency, G6PD (Glucose 6-phosphate dehydrogenase) deficiency. Patients who have this enzyme deficiency will need to be monitored with regular blood counts. In the ACZONE clinical trial program, 1.4% of about 3500 patients had this disorder which is consistent with the incidence in the general North American population. Certain populations, mainly males of African American descent, have a higher reported incidence of approximately 10-14%. QLT will undertake a post-approval Phase IV study in 50 acne patients who have G6PD deficiency and follow them for 6 months, after which QLT expects to submit an application to the FDA to re-evaluate the ACZONE label.

“We are very pleased with the FDA’s decision and confident in ACZONE’s potential as a new class of treatment for acne patients,� said Paul Hastings, President and Chief Executive Officer of QLT Inc. “ACZONE represents an important clinical advance in dermatology, has demonstrated safety and efficacy in over 4000 patients, and is an important first step for QLT to market our own products and establish our own commercial organization.�

ACZONE Gel 5% is the only acne treatment to harness the potential of dapsone in a topical formulation to provide patients with a convenient and effective therapy.

Link to comment
Share on other sites

Its realesed, I wonder what the deal is?

One of the links says it helps all forms of acne and is less irratating then other acne treatements. I hope this helps with clogged pores

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



  • Personalized Advice Quiz - All of Acne.org in just a few minutes


×